6 studies found for:    gdc0032
Show Display Options
Rank Status Study
1 Completed A Bioavailability and Pharmacokinetic Study of GDC-0032 in Healthy Volunteers
Condition: Healthy Volunteer
Intervention: Drug: GDC-0032
2 Recruiting A Dose Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors And in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer
Condition: Solid Cancers
Interventions: Drug: letrozole;   Drug: fulvestrant;   Drug: GDC-0032
3 Recruiting A Dose-Escalation Study to Assess the Safety, Tolerability, and Pharmacokinetics of GDC-0032 in Combination With Docetaxel or With Paclitaxel in Patients With HER2-negative Locally Recurrent or Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: GDC-0032;   Drug: Docetaxel;   Drug: Paclitaxel
4 Recruiting A Study of the Effect of Particle Size, Formulation and Food on the Pharmacokinetics of GDC-0032 in Healthy Volunteers
Condition: Healthy Volunteer
Intervention: Drug: GDC-0032
5 Completed A Drug Interaction Study of GDC-0032 Co-administered With Rifampin or Itraconazole in Healthy Volunteers
Condition: Healthy Volunteer
Interventions: Drug: GDC-0032;   Drug: Rifampin;   Drug: Itraconazole
6 Recruiting Lung-MAP: S1400 Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IIIB-IV Squamous Cell Lung Cancer
Conditions: Recurrent Non-small Cell Lung Cancer;   Squamous Cell Lung Cancer;   Stage IIIB Non-small Cell Lung Cancer;   Stage IV Non-small Cell Lung Cancer
Interventions: Biological: anti-B7H1 monoclonal antibody MEDI4736;   Drug: PI3 kinase inhibitor GDC-0032;   Drug: palbociclib isethionate;   Drug: FGFR inhibitor AZD4547;   Biological: rilotumumab;   Drug: docetaxel;   Drug: erlotinib hydrochloride;   Other: laboratory biomarker analysis

Indicates status has not been verified in more than two years